Please be advised that the question-and-answer period will be held at the close of the call. I would now like to turn the call over to Mr. Anthony Marucci, President and CEO of Celldex Therapeutics. You may proceed.
Good morning and thank you for joining us. I am Anthony Marucci, President and CEO of Celldex. Joining me on the call today, are Chip Catlin, our Senior Vice President and Chief Financial Officer; Dr. Tom Davis, our Senior Vice President and Chief Medical Officer and Dr. Tibor Keler, our Senior Vice President and Chief Scientific Officer.
The second quarter was an extremely productive quarter for Celldex. We had a number of key accomplishments which I want to take a few moments to review this morning before asking Chip to walk through the financial results. We will then open the call for your questions.
During the second quarter of 2012, Celldex continued to progress well with our two ongoing rindopepimut clinical trials. A pivotal ACT IV study in patients with newly diagnosed EGFRvIII-positive glioblastoma and the Phase II ReACT study in patients with recurring EGFRvIII-positive glioblastoma.
As we have discussed in the past, the ACT IV study will be conducted worldwide and approximately 19 countries around the globe at almost half the sites located outside the United States. This has been a major undertaking for our clinical team and they are doing a great job. In total, there are now more than 150 clinical sites around the world that have been selected to participate in the Phase III ACT IV study and our last count 78 of these sites were actively screening patients. The Phase II ReACT study is also well positioned with 25 study sites selected to participate and 17 actively screening.
In May, we also reported exciting preliminary results for our late second stage candidates in our pipeline CDX-011 in metastatic breast cancer. As most of you know, CDX-011 is a first-in-class next-generation antibody drug conjugate that targets a Celldex proprietary target Glycoprotein NMB or GPNMB.